Neuroblastoma patients are classified into low-, intermediate-, and high-risk groups based upon the age at diagnosis, tumor histopathology and differentiation, DNA index (ploidy), 11q deletion, and MYCN amplification status. This evidence concerns the gene MYCN and neoplasm.